Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lilly Asia Ventures Invests in Millin, a China Hemodialysis Company

publication date: Mar 24, 2016
Lilly Asia Ventures has made an investment of undisclosed size in Millin Enterprises, a Beijing company specializing in medical devices and treatment for kidney disease. The funding was an A round for Millin, which claims to supply about 50% of the medical devices and supplies used in Beijing's 130 hemodialysis centers.  The company also operates the Heilongjiang Sidley hospital that is dedicated to treating kidney disease. The hospital, which has 150 dialysis machines, opened in January 2015. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital